Title
Category
Credits
Event date
Cost
  • Biopsychosocial
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 APA
  • 1.00 ASWB-ACE
  • 1.00 Contact Hours/ Participation
$0.00
Aging is associated with a spectrum of cognitive changes ranging from normative mild alterations to clinically significant changes to debilitating impairments. Behavioral symptoms, too, are common and these can resemble non-cognitive mental health disorders. In this presentation, Dr. Ellison will review these cognitive syndromes, discuss assessment, and review decision-making and management issues relevant to the care of persons living with mild cognitive impairment and early dementia. 
  • Biopsychosocial
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 APA
  • 1.00 ASWB-ACE
  • 1.00 Contact Hours/ Participation
$0.00
In the last two decades, psychedelics have re-emerged as promising novel agents for treatment of a broad range of mental health conditions including depression, PTSD, substance use disorders, end-of-life anxieties, eating disorders, and more. Our understanding of their putative mechanisms of action has significantly evolved as well. Several Phase II and III clinical trials of psychedelic-assisted therapy (PAT) using psilocybin and MDMA are either complete or nearing completion, with some of these therapies projected to receive FDA approval within the next couple of years.
  • Biopsychosocial
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 APA
  • 1.00 ASWB-ACE
  • 1.00 Contact Hours/ Participation
$0.00
This forum uses Thomas Kohut’s recent book, Empathy and the Historical Understanding of the Human Past (Routledge, 2020), as a springboard for an interdisciplinary discussion of empathy and its role in understanding people in the past and in the present. 
  • Biopsychosocial
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 APA
  • 1.50 ASWB-ACE
  • 1.50 Contact Hours/ Participation
12/07/2024
$0.00
Part of the 2024 Virtual Roundtable Series, Minding the Gaps: Addressing Mental Health Through the Life Cycle 

Pages